U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24N2O4.ClH
Molecular Weight 404.887
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARMOTEROL HYDROCHLORIDE

SMILES

Cl.COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C3=C2C=CC(=O)N3)C=C1

InChI

InChIKey=SYCWERNQGSKYAG-QVRIGTRMSA-N
InChI=1S/C21H24N2O4.ClH/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21;/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26);1H/t13-,19+;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H24N2O4
Molecular Weight 368.4263
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Carmoterol is a long-acting β2-adrenoceptor agonist with a rapid onset of action and potent bronchodilating activity. Carmoterol has a similar onset of action compared to salbutamol and formoterol, and a faster onset of action compared to salmeterol. Furthermore, the duration of tracheal smooth muscle relaxation is longer for carmoterol compared to both formoterol and salmeterol. In asthmatic patients, the PK of carmoterol is proportional to the dose, and nonlinear accumulation of the drug after repeated dosing treatments is negligible. In patients with persistent asthma carmoterol 2 µg administered once daily is as effective as formoterol 12 µg twice daily. Safety and tolerability results are similar between carmoterol and formoterol. There were no significant changes in ECG results, blood pressure or serum potassium or glucose levels

Originator

Curator's Comment: Japanese journal of pharmacology (1991), 57, (2), 175-85.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.19 nM [Ki]
PubMed

PubMed

TitleDatePubMed
Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs.
2007
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sources: Kanniess F, Make BJ, Petruzzelli S. Acute effect of carmoterol, a long-acting β2-agonist, in patients with COPD [abstract] Proc Am Thorac Soc. 2008;5:A655. https://www.ncbi.nlm.nih.gov/pubmed/21232045
4 µg of 2 µg
Route of Administration: Respiratory
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:04:46 GMT 2023
Edited
by admin
on Fri Dec 15 16:04:46 GMT 2023
Record UNII
0WLO9P0V75
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARMOTEROL HYDROCHLORIDE
Common Name English
2(1H)-QUINOLINONE, 8-HYDROXY-5-((1R)-1-HYDROXY-2-(((1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
CHF-4226.01
Code English
2(1H)-QUINOLINONE, 8-HYDROXY-5-(1-HYDROXY-2-((2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)-, HYDROCHLORIDE, (R-(R*,R*))-
Common Name English
CARMOTEROL HCL
Common Name English
Code System Code Type Description
FDA UNII
0WLO9P0V75
Created by admin on Fri Dec 15 16:04:46 GMT 2023 , Edited by admin on Fri Dec 15 16:04:46 GMT 2023
PRIMARY
PUBCHEM
63951
Created by admin on Fri Dec 15 16:04:46 GMT 2023 , Edited by admin on Fri Dec 15 16:04:46 GMT 2023
PRIMARY
MESH
C074413
Created by admin on Fri Dec 15 16:04:46 GMT 2023 , Edited by admin on Fri Dec 15 16:04:46 GMT 2023
PRIMARY
CAS
137888-11-0
Created by admin on Fri Dec 15 16:04:46 GMT 2023 , Edited by admin on Fri Dec 15 16:04:46 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY